Lilly reinforces revenue guidance after strong Q1, but CEO says tariffs could impact business
Indianapolis-based Eli Lilly and Co. on Thursday posted 45% revenue growth in the first quarter of 2025 that topped Wall Street expectations, but the drugmaker’s stock dropped around 5% on earnings per share that did not meet analysts’ estimates.... Read More
